Share-based Payment Arrangement, Expense of Xenon Pharmaceuticals Inc. from 31 Dec 2013 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Xenon Pharmaceuticals Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2013 to 30 Sep 2025.
  • Xenon Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $13,705,000, a 5.4% increase year-over-year.
  • Xenon Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $53,191,000.
  • Xenon Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2024 was $50,717,000, a 57% increase from 2023.
  • Xenon Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2023 was $32,372,000, a 59% increase from 2022.
  • Xenon Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2022 was $20,376,000, a 103% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Xenon Pharmaceuticals Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $53,191,000 $13,705,000 +$703,000 +5.4% 01 Jul 2025 30 Sep 2025 10-Q 03 Nov 2025 2025 Q3
Q2 2025 $52,488,000 $13,713,000 -$1,003,000 -6.8% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $53,491,000 $12,174,000 +$2,774,000 +30% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $50,717,000 $13,599,000 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $13,002,000 01 Jul 2024 30 Sep 2024 10-Q 03 Nov 2025 2025 Q3
Q2 2024 $14,716,000 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $9,400,000 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1

Xenon Pharmaceuticals Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $50,717,000 +$18,345,000 +57% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $32,372,000 +$11,996,000 +59% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $20,376,000 +$10,359,000 +103% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $10,017,000 +$4,340,000 +76% 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
2020 $5,677,000 +$2,733,000 +93% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2019 $2,944,000 +$184,000 +6.7% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2021 2020 FY
2018 $2,760,000 +$524,000 +23% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2020 2019 FY
2017 $2,236,000 +$75,000 +3.5% 01 Jan 2017 31 Dec 2017 10-K 06 Mar 2019 2018 FY
2016 $2,161,000 -$1,568,000 -42% 01 Jan 2016 31 Dec 2016 10-K 07 Mar 2018 2017 FY
2015 $3,729,000 +$2,969,000 +391% 01 Jan 2015 31 Dec 2015 10-K 07 Mar 2018 2017 FY
2014 $760,000 +$185,000 +32% 01 Jan 2014 31 Dec 2014 10-K 08 Mar 2017 2016 FY
2013 $575,000 01 Jan 2013 31 Dec 2013 10-K 08 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.